Clinical trial
Comparison of the Risk of Acute Kidney Inury Between Patients With Type 2 Diabetes Exposed to Dapafliglozin and Those Exposed to Other Antidiabetic Treatments
NCT02695082 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Comparison of the Risk of Acute Kidney Inury Between Patients With Type 2 Diabetes Exposed to Dapafliglozin and Those Exposed to Other Antidiabetic Treatments
- Lead sponsor
- AstraZeneca
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 1, 2017
- Completion date
- November 30, 2020
- Enrollment
- Not reported
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.